XPEL, Inc. (NASDAQ:XPEL – Get Free Report)’s stock price gapped up prior to trading on Tuesday following a better than expected earnings announcement. The stock had previously closed at $29.22, but opened at $35.92. XPEL shares last traded at $35.09, with a volume of 110,413 shares traded.
The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.06. The business had revenue of $103.81 million during the quarter, compared to the consensus estimate of $97.40 million. XPEL had a net margin of 11.61% and a return on equity of 24.68%. XPEL’s quarterly revenue was up 15.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.24 EPS.
XPEL declared that its board has approved a share repurchase program on Tuesday, May 6th that allows the company to repurchase $50.00 million in outstanding shares. This repurchase authorization allows the company to purchase up to 5.4% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its stock is undervalued.
Institutional Trading of XPEL
XPEL Price Performance
The firm has a market cap of $924.84 million, a P/E ratio of 19.10 and a beta of 1.83. The company’s 50 day moving average is $29.19 and its two-hundred day moving average is $37.48.
About XPEL
XPEL, Inc sells, distributes, and installs protective films and coatings worldwide. The company offers automotive surface and paint protection film, headlight protection, and automotive and architectural window films, as well as proprietary DAP software. It also provides pre-cut film products, merchandise and apparel, ceramic coatings, and tools and accessories.
Read More
- Five stocks we like better than XPEL
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Mid-Cap Medical Stocks Outperforming the Market
- High Flyers: 3 Natural Gas Stocks for March 2022
- The Top-Ranked Insider Buys From April by Market Cap
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership?
Receive News & Ratings for XPEL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XPEL and related companies with MarketBeat.com's FREE daily email newsletter.